Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Valneva SE (AYJ0.F) Follow Compare 5.60 -0.30 (-5.08%) At close: April 17 at 3:29:02 PM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for AYJ0.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: AYJ0.F View More All News Press Releases SEC Filings Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® Valneva’s single-dose chikungunya vaccine authorised in Brazil Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 Exploring Three High Growth Tech Stocks In Europe Valneva SE Shareholding Declaration - March 2025 Is Valneva (VALN) the Best Performing NASDAQ Stock So Far in 2025? Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA